

JenKem Technology: High Quality PEG Products Manufacturer Since 2001


- Laboratory Synthesis to Large Scale GMP Manufacturing with Flexibility to Meet Customers' Specifications
- 109 Active Patents and over 600 Catalogue Products
- Supporting 9 Commercial Drugs and 11 Commercial Medical Devices Worldwide
- 21 Filed DMFs with US FDA and China CDE
- Following ICHQ7 Guidelines for GMP Manufacture
- Certified ISO 13485, ISO 9001, ISO 45001, ISO 14001, ISO 50001 and ISO 27001



Tianjin Facility: Annual Capacity of 2MT with Batch Size up to 10kg



Liaoning Facility: Annual Capacity of 12-20 MT with Batch Size up to 100 kg



Fatty Acid Side-Chains for Long-acting Polypeptides

- GMP Manufacture
- Custom Synthesis
- IND-Related Services

JenKem Technology USA Inc.

JenKem Technology USA Inc.

4105 W Spring Creek Pwky #606B
Plano, TX 75024, USA

Tel: +01-866-9JENKEM (+01-866-953-6536)
Tel: 1-972-673-0603
Fax: 1-469-327-2615
Email: sales@jenkemusa.com

Follow Us

X: <https://x.com/JenKemUSA>
LinkedIn: <https://www.linkedin.com/company/jenkem-technology-usa>
YouTube: <https://www.youtube.com/@JenKemUSA>

Your Premier Partner for Fatty Acid Side-Chain Products

JenKem Technology Co., Ltd (Stock Code: 688356.SH) is specialized in large scale GMP manufacture of high-quality drug delivery system products, custom synthesis and PEGylation services. The company supplies products for R&D, clinical trials, and commercial applications for pharmaceutical, biotechnology, medical devices, and diagnostics marketplaces worldwide since 2001.

Committed to the principle of "Leading the Biomedical Innovation with Material Innovation," JenKem Technology shows respect for and readiness to aid in your innovative endeavors. As of July 2024, JenKem Technology's products are used in 9 commercial drugs, 11 commercial medical devices, and more than 70 innovative drug and medical device projects in pre-clinical and clinical stages worldwide.

JenKem Technology has the capabilities to supply high quality fatty acid side-chain products in both non-GMP and GMP grade, from small scale to large scale. With product purity of 98% or higher and large-scale manufacturing capability for batch sizes of 10 kg to 100 kg, we have a quality control system in place to ensure our customers receive high product quality and batch-to-batch consistency from early-stage research and development through to commercial-scale manufacturing.



Long-acting Polypeptide Fatty Acid Side-Chain

Currently, the most popular long-acting GLP-1 receptor agonists available incorporate fatty acid side-chain modification technology. Glucagon-like Peptide-1 (GLP-1), a peptide hormone secreted by human intestinal tract to stimulate insulin secretion from pancreatic β-cells, plays a central role in coordinating postprandial glucose homeostasis, food intake and intestinal motility. GLP-1 receptor agonists have been used extensively in the treatment of type II diabetes and obesity.




Fig 1 C18 Fatty Acid Side Chain




Fig 2 C20 Fatty Acid Side Chain

Services Provided by JenKem Technology

- Fatty Acid Side-Chain Catalog Manufacture
- Fatty Acid Side-Chain Custom Synthesis
- Customized Molecular Coupling Services
- Characterization of Modified Polypeptide(s) and Its Catabolites
- Quality Studies Related to Clinical Study

Long-acting Polypeptide Fatty Acid Side-Chain

Product Name	Purity	CAS No.	Structure
tBuO-Ste-Glu(AEEA-AEEA-OH)-OtBu	≥ 98%	1118767-16-0	
Ste-Glu-AEEA-AEEA-OSU	≥ 90%	1169630-40-3	
tBuO-Ste-Glu(AEEA-AEEA-OSU)-OtBu	≥ 95%	1118767-15-9	
Fmoc-Lys(tBuO-Ste-Glu(AEEA-AEEA)-OtBu)-OH	≥ 98%	1662688-20-1	
tBuO-ICO-Glu(AEEA-AEEA-OH)-OtBu	≥ 98%	1188328-37-1	
ICO-Glu-AEEA-AEEA-OSU	≥ 90%	1188328-38-2	
tBuO-ICO-Glu(AEEA-AEEA-OSU)-OtBu	≥ 95%	1118767-17-1	
Fmoc-Lys(tBuO-ICO-Glu(AEEA-AEEA)-OtBu)-OH	≥ 98%	2460751-66-8	

Should the desired structures not be listed in our catalogue, please do not hesitate to make an inquiry. JenKem Technology is prepared to offer custom synthesis for custom side-chain compounds to provide comprehensive support for your R&D initiatives.